Search
EHA welcomes European Parliament backing for SoHO legislation
EHA welcomes the European Parliament’s backing for SoHO legislation that puts patient safety and supply sustainability first.
Read moreEHA-KCS Hematology Tutorial on Lymphoma and Multiple Myeloma
Dates: March 14-16, 2019
Location: Almaty, Kazakhstan
Chairs: G Gaidano, D Kaidarova
Co-chairs: S Gabbasova, B Afanasyev
This meeting will be held in English and offer a simultaneous translation to Russian.
EHA Statement: Our sustained solidarity with the hematology community in Ukraine
Friday, February 24 marks one year of war. The European Hematology Association (EHA) stands in solidarity with our colleagues and friends in Ukraine.
Read moreEHA Statement of Solidarity with local communities in Türkiye and Syria
The European Hematology Association (EHA) is deeply concerned about the situation in southern Türkiye and northern Syria: Monday's earthquakes and aftershocks have killed thousands of people and destroyed innumerable buildings, while freezing temperatures and damaged roads are hampering rescue efforts.
Read moreHelp disseminate IVDR Questionnaire - Share with diagnostic laboratories in your network
The new EU Regulation on in vitro diagnostic medical devices (IVDR) will come into full effect per May 26, 2022 and will have substantial consequences for diagnostic laboratories.
Read moreMeet Irene Roberts, our September volunteer of the month
Can you tell us what you do for EHA and when you started?
I joined EHA in 2003 and shortly afterwards I was lucky enough to be elected as a member of the EHA Board.
Meet Irene Roberts, our September volunteer of the month
Can you tell us what you do for EHA and when you started?
I joined EHA in 2003 and shortly afterwards I was lucky enough to be elected as a member of the EHA Board.
The European Parliament adopts the Regulation on Substances of Human Origins (SoHO)
On April 24, the European Parliament gave its final endorsement to the regulation on Substances of Human Origin (SoHO).
Read moreEvaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes
Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes
Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- »